RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Basi molecolari, aspetti fisiopatologici e terapeutici delle malattie lisosomiali
• 2 - Patogenesi molecolare delle malattie del motoneurone come tool per l’identificazione di nuovi approcci terapeutici biomolecolari e cellulari
• 3 - Studio delle basi molecolari per un'ottimizzazione della terapia mirata con inibitori delle tirosin-kinasi: il caso della leucemia mieloide cronica e di altre neoplasie ematologiche
• 4 - PROGRESSIONE DA MGUS A MIELOMA MULTIPLO: PATOGENESI MOLECOLARE, IDENTIFICAZIONE DI POTENZIALI MARCATORI PROGNOSTICI E SVILUPPO PRECLINICO DI RAZIONALI APPROCCI CHEMIOPREVENTIVI
• 5 - Approccio di proteomica per l'individuazione di nuovi marcatori molecolari nelle malattie neurodegenerative
• 6 - Geni dell'angiogenesi indotti da ipossia: fattori di suscettibilità nella Sclerosi Laterale Amiotrofica ?
• 7 - Aspetti funzionali della cross-correzione e implicazioni terapeutiche per la cura di malattie genetiche da accumulo lisosomale.
• 8 - Studio delle basi molecolari e cellulari della risposta alla terapia mirata con inibitori delle tirosin-kinasi per l'ottimizzazione del trattamento delle leucemia Philadelphia positive
• 9 - Intolleranza alle proteine con lisinuria: sviluppo ed analisi di un modello genetico murino di tipo condizionale e di modelli cellulari umani
• 10 - BETA AMILOIDE: IL PRINCIPALE RESPONSABILE DELLA NEURODEGENERAZIONE NELLA MALATTIA DI ALZHEIMER O UN NUOVO NEUROMODULATORE?

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • GENETICA MEDICA
  • PEDIATRIA GENERALE E SPECIALISTICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
• HUMAN NECESSITIES
  • AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

Classificazione geografica

• Regione: Campania

Bibliografia

Asano, N., Ishii, S., Kizu, H., Ikeda, K., Yasuda, K., Kato, A., Martin, O. R., and Fan, J. Q. (2000). In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem 267, 4179-4186.
Barton, N. W., Brady, R. O., Dambrosia, J. M., Di Bisceglie, A. M., Doppelt, S. H., Hill, S. C., Mankin, H. J., Murray, G. J., Parker, R. I., Argoff, C. E., and et al. (1991). Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324, 1464-1470.
Cheng, S. H., and Smith, A. E. (2003). Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther 10, 1275-1281.
Cosma, M. P., Pepe, S., Annunziata, I., Newbold, R. F., Grompe, M., Parenti, G., and Ballabio, A. (2003). The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 113, 445-456.
Cox, T., Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebicek, M., Platt, F., Butters, T., Dwek, R., Moyses, C., et al. (2000). Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355, 1481-1485.
D'Azzo, A. (2003). Gene transfer strategies for correction of lysosomal storage disorders. Acta Haematol 110, 71-85.
D’Azzo A., Andria G., Strisciuglio P, Galjaard H.: Galactosialidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and Molecular bases of Inherited Disease Mc Graw-Hill, New York, NY, pp 3811-3826; 2001
Desnick, R. J., and Schuchman, E. H. (2002). Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 3, 954-966.
Di Natale, P., Di Domenico, C., Villani, G. R., Lombardo, A., Follenzi, A., and Naldini, L. (2002). In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors. Eur J Biochem 269, 2764-2771.
Dierks, T., Schmidt, B., Borissenko, L. V., Peng, J., Preusser, A., Mariappan, M., and von Figura, K. (2003). Multiple Sulfatase Deficiency Is Caused by Mutations in the Gene Encoding the Human C(alpha)-Formylglycine Generating Enzyme. Cell 113, 435-444.
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., and Desnick, R. J. (2001). Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med 345, 9-16.
Fan, J. Q., Ishii, S., Asano, N., and Suzuki, Y. (1999). Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5, 112-115.
Frustaci, A., Chimenti, C., Ricci, R., Natale, L., Russo, M. A., Pieroni, M., Eng, C. M., and Desnick, R. J. (2001). Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 345, 25-32.
Huang, J. Q., Trasler, J. M., Igdoura, S., Michaud, J., Hanal, N., and Gravel, R. A. (1997). Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 6, 1879-1885.
Kakkis, E. D., Muenzer, J., Tiller, G. E., Waber, L., Belmont, J., Passage, M., Izykowski, B., Phillips, J., Doroshow, R., Walot, I., et al. (2001). Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344, 182-188.
Kornfeld, S., and Mellman, I. (1989). The biogenesis of lysosomes. Annu Rev Cell Biol 5, 483-525.
Krivit, W. (2002). Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr 49, 359-378.
Krivit, W., Aubourg, P., Shapiro, E., and Peters, C. (1999a). Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr Opin Hematol 6, 377-382.
Krivit, W., Peters, C., and Shapiro, E. G. (1999b). Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 12, 167-176.
Neufeld EF, Muenzer J. (2001). The Mucopolisaccaridoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and Molecular bases of Inherited Disease Mc Graw-Hill, New York, NY, pp 3421-3452
Okumiya, T., Ishii, S., Takenaka, T., Kase, R., Kamei, S., Sakuraba, H., and Suzuki, Y. (1995). Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Biochem Biophys Res Commun 214, 1219-1224.
Parenti, G., Meroni, G., and Ballabio, A. (1997). The sulfatase gene family. Curr Opin Genet Dev 7, 386-391.
Platt, F. M., Neises, G. R., Reinkensmeier, G., Townsend, M. J., Perry, V. H., Proia, R. L., Winchester, B., Dwek, R. A., and Butters, T. D. (1997). Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276, 428-431.
Pshezhetsky, A. V., and Ashmarina, M. (2001). Lysosomal multienzyme complex: biochemistry, genetics, and molecular pathophysiology. Prog Nucleic Acid Res Mol Biol 69, 81-114.
Sawkar, A. R., Cheng, W. C., Beutler, E., Wong, C. H., Balch, W. E., and Kelly, J. W. (2002). Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A 99, 15428-15433.
Schmidt, B., Selmer, T., Ingendoh, A., and von Figura, K. (1995). A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency. Cell 82, 271-278.
Suzuki Y, Akihiro O, Namba E: β-galactosidase deficiency (β-galactosidosis): GM1 gangliosidosis and Morquio B disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and Molecular bases of Inherited Disease Mc Graw-Hill, New York, NY, pp 3775-3809
Thomas G.H. (2001). Disorders of glycoprotein degradation: a-Mannosidosis, b-Mannosidosis, Fucosidosis, and sialidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and Molecular bases of Inherited Disease Mc Graw-Hill, New York, NY, pp 3507-3533.
Van den Hout, H., Reuser, A. J., Vulto, A. G., Loonen, M. C., Cromme-Dijkhuis, A., and Van der Ploeg, A. T. (2000). Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356, 397-398.
Villani, G. R., Follenzi, A., Vanacore, B., Di Domenico, C., Naldini, L., and Di Natale, P. (2002). Correction of mucopolysaccharidosis type IIIb fibroblasts by lentiviral vector-mediated gene transfer. Biochem J 364, 747-753.
Wada, R., Tifft, C. J., and Proia, R. L. (2000). Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci U S A 97, 10954-10959.
Wenger, D. A., Coppola, S., and Liu, S. L. (2003). Insights into the diagnosis and treatment of lysosomal storage diseases. Arch Neurol 60, 322-328.
Wraith, J. E. (2002). Lysosomal disorders. Semin Neonatol 7, 75-83.

Parole Chiave

MALATTIE LISOSOMIALI; MUCOPOLISACCARIDOSI; M. DI POMPE; GANGLIOSIDOSI GM1; GALATTOSIALIDOSI; TERAPIA ENZIMATICA SOSTITUTIVA; TERAPIA GENICA